Prophylactic beta blockade preserves left ventricular ejection fraction in HER-2-overexpresssing breast cancer patients receiving trastuzumab: Primary results of the MANTICORE randomised controlled trial. The gene discussed is ERBB2; the disease is breast carcinoma.